▶ GLP-1 · SUBTOPIC · DOSING LITERATURE
GLP-1 Dosing Literature
For Laboratory Research Use Only. The content below describes dose ranges as reported in peer-reviewed publications. This page does not recommend any dose for human use. No clinical claim is made. Always consult the original source publication.
SCOPE OF THIS PAGE
This page documents the published-literature dose ranges that appear in trials and animal studies of GLP-1. Every dose mention is bound to a citation (author, year, PMID where available). The PEPPUDEX wiki phrases these as descriptive observations of the research record, not as instructions to the reader.
ROUTES OF ADMINISTRATION IN PUBLISHED RESEARCH
The published research record for GLP-1 reports the following route(s) of administration: Subcutaneous (in published trials). Route selection in a study reflects pharmacokinetic considerations specific to that protocol and is not a recommendation for any human use of GLP-1.
PHARMACOKINETIC HALF-LIFE
Published pharmacokinetic data report a half-life for GLP-1 of approximately ~6 days. Half-life is the kinetic parameter that frames the dosing rhythm chosen in trial design. It is a measurement, not a recommendation.
CITED DOSE RANGES IN THE LITERATURE
The peer-reviewed sources below report dose ranges, frequencies, and durations used in studies of GLP-1. Refer to the original publication for full protocol detail.
- Jastreboff AM, Kaplan LM, Frías JP, et al. (2023) reports the GLP-1 protocol used in Triple-Hormone-Receptor Agonist GLP-1 for Obesity · A Phase 2 Trial, published in N Engl J Med. PMID 37366315. See the source for the protocol-level dose range, frequency, and duration. link
- Eli Lilly and Company (2021) reports the GLP-1 protocol used in A Study of GLP-1 reference in Participants With Obesity (Phase 2), published in ClinicalTrials.gov. NCT04881760. See the source for the protocol-level dose range, frequency, and duration. link
DOSING Q+A FROM LITERATURE
The questions below summarise dosing-relevant entries from the literature record. Each answer is descriptive of published material and is not a recommendation.
▶ What was the Phase 2 result?
The published Phase 2 NEJM trial (Jastreboff et al., 2023, PMID 37366315; NCT04881760) reported least-squares mean body-weight reductions of -8.7% to -24.2% across dose arms at 48 weeks vs -2.1% with placebo. Those numbers are the property of the publishing investigators, not claims of this product.
▶ What is the half-life of GLP-1?
Published pharmacokinetic data indicate a terminal half-life around six days, consistent with once-weekly dosing in trials.
▶ How is GLP-1 reconstituted?
Reconstitute lyophilized GLP-1 with USP-grade sterile diluent per laboratory protocol. The PEPPUDEX calculator at /calculator returns volume-per-dose math given vial mg, BAC mL, and target mcg.
▶ Can GLP-1 be stacked with GLP-2?
No published research supports simultaneous use of multiple incretin agonists. They engage overlapping pathways and combined use is unstudied. This wiki does not recommend any human dose or combination.
▶ What were the most common side effects in Phase 2?
Gastrointestinal events (nausea, vomiting, diarrhea) were the dominant adverse-event class, dose-dependent and mostly mild-to-moderate. Dose-dependent heart-rate increases peaked at 24 weeks and declined thereafter.
▶ How long do GLP-1 cycles last in published trials?
The published Phase 2 trial dosed once-weekly for 48 weeks. Phase 3 TRIUMPH durations vary by sub-study; consult ClinicalTrials.gov for current protocols.
▶ Does GLP-1 affect heart rate?
Phase 2 reported dose-dependent increases in resting heart rate peaking around 24 weeks before declining. This is a class-level signal for incretin agonists at higher doses.
▶ Is GLP-1 oral or injectable in trials?
Published trials use subcutaneous injection only. There is no approved or studied oral formulation as of the Phase 2 publication.
STORAGE OF THE REFERENCE COMPOUND
Lyophilized · 2–8 °C, 12+ months
Reconstituted · 2–8 °C, 28 days
Storage conditions describe the stability of the research-grade reference material, not a dosing protocol.
RECONSTITUTION MATH (CALCULATOR)
The PEPPUDEX reconstitution calculator at /calculator returns volume-per-dose math given vial mg, BAC mL, and a target dose in mcg. The calculator performs arithmetic only. It does not recommend a dose. Any number entered by a researcher must come from their own protocol design or the cited literature.
REGULATORY CONTEXT
FDA · Investigational compound · NOT FDA-approved · TRIUMPH Phase 3 program ongoing as of 2026-05.
WADA · Not currently listed on the WADA Prohibited List (2026).
RELATED PAGES
▶ LAST UPDATED · 2026-05-19